Kidney Cancer Clinical Trial

Clinical Trial Finder Kidney Cancer Trials

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

See Locations Near You

Summary

To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

18 years of age or older
Pathology-confirmed diagnosis of metastatic RCC
At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging
Written informed consent.

Specific inclusion criteria:

arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
arm 2: planned to be treated with non-ICI therapy

Exclusion Criteria:

-Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study

Study is for people with:

Kidney Cancer

Estimated Enrollment:

22

Study ID:

NCT04508725

Recruitment Status:

Active, not recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University School of Medicine
Stanford California, 94305, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

22

Study ID:

NCT04508725

Recruitment Status:

Active, not recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider